Artesunate induces necrotic cell death in schwannoma cells

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  Button, R W ^a   Lin, F ^b   Ercolano, E ^a   Vincent, J H ^a   Hu, B ^a   Hanemann, C O ^a   Luo, S ^a  

^a PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ARTEMISININ; ARTESUNATE; CHLOROQUINE; STAUROSPORINE; AGFG1 PROTEIN, HUMAN; ARTEMISININ DERIVATIVE; NUCLEOPORIN; REACTIVE OXYGEN METABOLITE; RNA BINDING PROTEIN; SCAVENGER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL DEATH; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY ASSAY; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; NECROPTOSIS; NEURILEMOMA; PRIORITY JOURNAL; TUMOR CELL; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM; NECROSIS; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; ARTEMISININS; AUTOPHAGY; CELL LINE, TUMOR; CHLOROQUINE; DRUG SYNERGISM; FREE RADICAL SCAVENGERS; HUMANS; NECROSIS; NEURILEMMOMA; NUCLEAR PORE COMPLEX PROTEINS; REACTIVE OXYGEN SPECIES; RNA-BINDING PROTEINS;

EID: 84928008960     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.434     Document Type: Article

References (58)

1. Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985; 228: 1049-1055.
2. Pandey AV, Tekwani BL, Singh RL, Chauhan VS. Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. J Biol Chem1999; 274: 19383-19388.
3. Enserink M. If artemisinin drugs fail, what's plan B? Science 2010; 328: 846.
4. Efferth T, Volm M. Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate. In Vivo 2005; 19: 225-232.
5. Lai H, Singh NP. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett 1995; 91: 41-46.
6. Singh NP, Lai H. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci 2001; 70: 49-56.
7. Efferth T, Bode ME, Schulten HG, Thelen P, Granzen B, Beniers AJ et al. Differential expression of the lung resistance-related protein/major vault protein in the histological compartments of nephroblastomas. Int J Oncol 2001; 19: 163-168.
8. Youns M, Efferth T, Reichling J, Fellenberg K, Bauer A, Hoheisel JD. Gene expression profiling identifies novel key players involved in the cytotoxic effect of Artesunate on pancreatic cancer cells. Biochem Pharmacol2009; 78: 273-283.
9. Efferth T, Giaisi M, Merling A, Krammer PH, Li-Weber M. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS One 2007; 2: e693.
10. Dell'Eva R, Pfeffer U, Vene R, Anfosso L, Forlani A, Albini A et al. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol2004; 68: 2359-2366.
11. Chen H, Sun B, Pan S, Jiang H, Sun X. Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer drugs 2009; 20: 131-140.
12. Hou J, Wang D, Zhang R, Wang H. Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 2008; 14: 5519-5530.
13. Berger TG, Dieckmann D, Efferth T, Schultz ES, Funk JO, Baur A et al. Artesunate in the treatment of metastatic uveal melanoma-first experiences. Oncol Rep 2005; 14: 1599-1603.
14. Hyman BT, Yuan J. Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology. Nat Rev Neurosci 2012; 13: 395-406.
15. Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009; 137: 1112-1123.
16. He S, Wang L, Miao L, Wang T, Du F, Zhao L et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 2009; 137: 1100-1111.
17. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009; 325: 332-336.
18. Hamacher-Brady A, Stein HA, Turschner S, Toegel I, Mora R, Jennewein N et al. Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. J Biol Chem2011; 286: 6587-6601.
19. Handrick R, Ontikatze T, Bauer KD, Freier F, Rubel A, Durig J et al. Dihydroartemisinin induces apoptosis by a Bak-dependent intrinsic pathway. Mol Cancer Ther 2010; 9: 2497-2510.
20. Li PC, Lam E, Roos WP, Zdzienicka MZ, Kaina B, Efferth T. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res2008; 68: 4347-4351.
21. Tran KQ, Tin AS, Firestone GL. Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits cyclin-dependent kinase-4 promoter activity and expression by disrupting nuclear factor-kappaB transcriptional signaling. Anticancer Drugs 2014; 25: 270-281.
22. Zhang HT, Wang YL, Zhang J, Zhang QX. Artemisinin inhibits gastric cancer cell proliferation through upregulation of p53. Tumour Biol 2014; 35: 1403-1409.
23. Zhao Y, Jiang W, Li B, Yao Q, Dong J, Cen Y et al. Artesunate enhances radiosensitivity of human non-small cell lung cancer A549 cells via increasing NO production to induce cell cycle arrest at G2/M phase. Int Immunopharmacol2011; 11: 2039-2046.
24. Hu CJ, Zhou L, Cai Y. Dihydroartemisinin induces apoptosis of cervical cancer cells via upregulation of RKIP and downregulation of bcl-2. Cancer Biol Ther2014; 15: 279-288.
25. Zhang CZ, Zhang H, Yun J, Chen GG, Lai PB. Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochem Pharmacol2012; 83: 1278-1289.
26. Ammoun S, Hanemann CO. Emerging therapeutic targets in schwannomas and other merlin-deficient tumors. Nat Rev Neurol 2011; 7: 392-399.
27. Casadei GP, Komori T, Scheithauer BW, Miller GM, Parisi JE, Kelly PJ. Intracranial parenchymal schwannoma. A clinicopathological and neuroimaging study of nine cases. J Neurosurg 1993; 79: 217-222.
28. Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA1995; 92: 10854-10858.
29. Morrow KA, Das S, Metge BJ, Ye K, Mulekar MS, Tucker JA et al. Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation. J Biol Chem2011; 286: 40376-40385.
30. Zhou L, Hanemann CO. Merlin, a multi-suppressor from cell membrane to the nucleus. FEBS Lett2012; 586: 1403-1408.
31. Hara H, Friedlander RM, Gagliardini V, Ayata C, Fink K, Huang Z et al. Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci USA1997; 94: 2007-2012.
32. Luo S, Garcia-Arencibia M, Zhao R, Puri C, Toh PP, Sadiq O et al. Bim inhibits autophagy by recruiting Beclin 1 to microtubules. Mol Cell 2012; 47: 359-370.
33. Manns J, Daubrawa M, Driessen S, Paasch F, Hoffmann N, Loffler A et al. Triggering of a novel intrinsic apoptosis pathway by the kinase inhibitor staurosporine: activation of caspase- 9 in the absence of Apaf-1. FASEB J 2011; 25: 3250-3261.
34. Lai HC, Singh NP, Sasaki T. Development of artemisinin compounds for cancer treatment. Invest New Drugs 2013; 31: 230-246.
35. Chen T, Li M, Zhang R, Wang H. Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med 2009; 13: 1358-1370.
36. Mercer AE, Copple IM, Maggs JL, O'Neill PM, Park BK. The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. J Biol Chem2011; 286: 987-996.
37. Mercer AE, Maggs JL, Sun XM, Cohen GM, Chadwick J, O'Neill PM et al. Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. J Biol Chem2007; 282: 9372-9382.
38. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res1993; 53: 3976-3985.
39. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995; 81: 801-809.
40. Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996; 84: 299-308.
41. Luo S, Rubinsztein DC. Huntingtin promotes cell survival by preventing Pak2 cleavage. J Cell Sci2009; 122: 875-885.
42. Galluzzi L, Kroemer G. Necroptosis: a specialized pathway of programmed necrosis. Cell 2008; 135: 1161-1163.
43. Yuan J, Kroemer G. Alternative cell death mechanisms in development and beyond. Genes Dev 2010; 24: 2592-2602.
44. Degterev A, Maki JL, Yuan J. Activity and specificity of necrostatin-1, small-molecule inhibitor of RIP1 kinase. Cell Death Differ 2013; 20: 366.
45. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4: 313-321.
46. Belmokhtar CA, Hillion J, Segal-Bendirdjian E. Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms. Oncogene 2001; 20: 3354-3362.
47. Sun L, Wang H, Wang Z, He S, Chen S, Liao D et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012; 148: 213-227.
48. Wang H, Sun L, Su L, Rizo J, Liu L, Wang LF et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell 2014; 54: 133-146.
49. Klionsky DJ. The molecular machinery of autophagy: unanswered questions. J Cell Sci 2005; 118: 7-18.
50. Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Thompson CB et al. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 2004; 6: 1221-1228.
51. Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J 2007; 26: 1749-1760.
52. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008; 4: 151-175.
53. Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 2007; 3: 452-460.
54. Moreau K, Luo S, Rubinsztein DC. Cytoprotective roles for autophagy. Curr Opin Cell Biol 22: 206-211.
55. Boya P, Gonzalez-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N et al. Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 2005; 25: 1025-1040.
56. Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res 2008; 68: 5236-5245.
57. Ammoun S, Provenzano L, Zhou L, Barczyk M, Evans K, Hilton DA et al. Axl/Gas6/NFkappaB signalling in schwannoma pathological proliferation, adhesion and survival. Oncogene 2013; 33: 336-346.
58. Rosenbaum C, Kluwe L, Mautner VF, Friedrich RE, Muller HW, Hanemann CO. Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients. Neurobiol Dis 1998; 5: 55-64.